It is a department that develops and investigates food with the aim to create a new value of products and to ensure differentiated product development; the department has a natural substance food research team.

The food research institute is making an effort to create happy food culture through innovative functional substance search, natural anti-bacteria new material research, functional food development, spice research, a variety of dosage form technology development, and consumer taste monitoring, among others. The institute is also conducting research on technology establishment until a product is produced through the product scale-up.

Central Research Institute Food Research Team consists of the preferred food research Institue and the health food research Institue to reinforce specialties and merits of the pharmaceutical food research institute, heading towards independent and differentiated research activities. It has become a driving force of an unlimited growth by the continuous development and succession of the product development business field, including raw material standardization and new product development, etc., as well as of the dosage form technology development and tablet specialization field.

Moreover, through Industry-Academy co-research, it performs a mid-long term research development project and has become an institute that develops functional new substances to enhance its status as the next-generation food-medical specializing research institute and, simultaneously, the institute that makes a great contribution to the sales.

Medicine Research Institute focuses on research, development of Oriental medicine, and the specialized medicine field for “Human Healthcare Brand Company.”

In order to actively cope with the change of the every-changing industry market in and outside of Korea, it has made a progress in developing specialized Oriental medicine products and differentiated general medicines, such as Woo Hwang Chong Shim Won and Tok n Tok Topical Solution, etc.

Additionally, it has added fresh fuel to the development of incrementally modified drugs to treat the diseases of the nervous system, urinary system, alimentary system, and circulatory system, etc., as well as developed into a global pharmaceutical company with bold research investment.

Rather than focusing on the production of simple generics, it is making an effort to create efficiency-type OTC (over-the-counter) and healthcare products in the short term and to develop DDS (Drug Delivery System)-type super-generics (incrementally modified drug) in the mid-long term; it will also put forth its spurt in the continuous investment and effort towards the dream of global medicine development through the highly specialized technology.

Rather than focusing on the production of simple generics, it is making an effort to create efficiency-type OTC (over-the-counter) and healthcare products in the short term and to develop DDS (Drug Delivery System)-type super-generics (incrementally modified drug) in the mid-long term; it will also put forth its spurt in the continuous investment and effort towards the dream of global medicine development through the highly specialized technology.

As the advance guard of the new drug development, Kwangdong Pharmaceutical R&D I is constructing personnel, material system according to the international standards through active R&D investment, and its excellent R&D talents are striving in the original and differentiated medicine development based on the new accumulated drug development experiences and infrastructure.

Furthermore, it is pushing strategic partnerships ahead with global pharmaceutical companies for brand-new drug development and making a progress of a wide joint research with the specialists in and outside of Korea for the global innovative new drug development.

R&D I has secured a global research advising group and established a new dosage form researching team that investigates a new dosage form and ODF as an alternative to the generic market with which the team has a fierce competition.

Through these measures, R&D I will create high value-added new drugs and Kwangdong Pharmaceutical will spare no investment to ensure that R&D I can focus on efficiency increase and successful outcomes.